Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weight Of Emergency Contraceptive Data Does Not Support Label Change

This article was originally published in The Pink Sheet Daily

Executive Summary

Data are "conflicting and too limited to make a definitive conclusion," FDA says after reviewing scientific data concerning effectiveness of Plan B One Step and other 1.5mg levonorgestrel emergency contraceptives in women weighing more than 165 pounds.

You may also be interested in...



UK Recommends Double Emergency Contraceptive Dose To Counter Enzyme Inducers

Women taking CYP3A4 enzyme inducers or St. John's wort should use double the standard dose of levonorgestrel, if using it as an emergency contraceptive, to compensate for reduced plasma levels of the ingredient, UK agency says.

UK Recommends Double Emergency Contraceptive Dose To Counter Enzyme Inducers

Women taking CYP3A4 enzyme inducers or St. John's wort should use double the standard dose of levonorgestrel, if using it as an emergency contraceptive, to compensate for reduced plasma levels of the ingredient, UK agency says.

Court Ruling Compels Emergency Contraceptives Over The Counter

Under a federal judge’s order, FDA must reverse its denial of the Center for Reproductive Rights’ 12-year-old citizen petition and allow universal OTC access to Plan B One-Step and equivalent levonorgestrel-based emergency contraceptives within 30 days.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel